Guselkumab superior to Humira in phase 3 trial for moderate to severe psoriasis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • In VOYAGE 1 trial, guselkumab was superior to adalimumab (Humira) in patients with moderate to severe psoriasis.

Why this matters

  • Results allow clinicians to tailor treatment to patient needs.
Study design
  • Phase 3 randomized, double-blind, placebo and active comparator cont...